Home >> Research Area >>Membrane Transporter/Ion Channel>>AMPAR>> GYKI 47261 dihydrochloride

GYKI 47261 dihydrochloride

AMPA receptor antagonist, non-competitive and selective CAS# 1217049-32-5

GYKI 47261 dihydrochloride

Catalog No. BCC7566----Order now to get a substantial discount!

Product Name & Size Price Stock
GYKI 47261 dihydrochloride: 5mg $115 In Stock
GYKI 47261 dihydrochloride: 10mg Please Inquire In Stock
GYKI 47261 dihydrochloride: 20mg Please Inquire Please Inquire
GYKI 47261 dihydrochloride: 50mg Please Inquire Please Inquire
GYKI 47261 dihydrochloride: 100mg Please Inquire Please Inquire
GYKI 47261 dihydrochloride: 200mg Please Inquire Please Inquire
GYKI 47261 dihydrochloride: 500mg Please Inquire Please Inquire
GYKI 47261 dihydrochloride: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of GYKI 47261 dihydrochloride

Number of papers citing our products

Chemical structure

GYKI 47261 dihydrochloride

3D structure

Chemical Properties of GYKI 47261 dihydrochloride

Cas No. 1217049-32-5 SDF Download SDF
PubChem ID 46861544 Appearance Powder
Formula C18H17Cl3N4 M.Wt 395.71
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO
Chemical Name 4-(8-chloro-2-methyl-11H-imidazo[1,2-c][2,3]benzodiazepin-6-yl)aniline;dihydrochloride
SMILES CC1=CN2C(=N1)CC3=C(C=C(C=C3)Cl)C(=N2)C4=CC=C(C=C4)N.Cl.Cl
Standard InChIKey HUNSEMNKAFDVDI-UHFFFAOYSA-N
Standard InChI InChI=1S/C18H15ClN4.2ClH/c1-11-10-23-17(21-11)8-13-2-5-14(19)9-16(13)18(22-23)12-3-6-15(20)7-4-12;;/h2-7,9-10H,8,20H2,1H3;2*1H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of GYKI 47261 dihydrochloride

DescriptionNon-competitive AMPA receptor antagonist (IC50 = 2.5 μM). Displays broad spectrum anticonvulsive activity and neuroprotective effects in vivo.

GYKI 47261 dihydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

GYKI 47261 dihydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of GYKI 47261 dihydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.5271 mL 12.6355 mL 25.271 mL 50.5421 mL 63.1776 mL
5 mM 0.5054 mL 2.5271 mL 5.0542 mL 10.1084 mL 12.6355 mL
10 mM 0.2527 mL 1.2636 mL 2.5271 mL 5.0542 mL 6.3178 mL
50 mM 0.0505 mL 0.2527 mL 0.5054 mL 1.0108 mL 1.2636 mL
100 mM 0.0253 mL 0.1264 mL 0.2527 mL 0.5054 mL 0.6318 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on GYKI 47261 dihydrochloride

GYKI 47261 dihydrochloride is a selective and non-competitive antagonist of AMPA receptor with IC50 value of 2.5 μM [1].

The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor) is an ionotropic transmembrane receptor for glutamate and mediates fast synaptic transmission in the central nervous system. AMPA receptors are oligomeric assemblies of four protein subunits, GluR1-4.

GYKI 47261 dihydrochloride is a selective and non-competitive AMPA receptor antagonist. In isolated cerebellar Purkinje cells, GYKI 47261 (10 μM) inhibited currents induced by kainate or AMPA in a non-competitive way [1]. In rat hepatocytes, GYKI-47261 (10 μM) significantly increased CYP2E1 activity. In human hepatocytes, GYKI-47261 produced the maximal induction at 0.01 μM [2].

In mice, GYKI 47261 induced muscle relaxant effects with ED50 values of 15.8-36.5 mg/kg. In a transient focal ischemia rat model, GYKI 47261 significantly reduced infarct size by 62.3-67.4%. In mice, GYKI 47261 effectively reduced oxotremorine-induced tremor and inhibited MPTP-induced neurotoxicity [1]. In Parkinson’s disease rat model, administration of GYKI-47261 and MK-801 completely normalized the response shortening induced by levodopa. In monkeys, administration of amantadine and GYKI-47261 significantly reduced dyskinesias induced by levodopa by 51% [3].

References:
[1].  Abrahám G, Sólyom S, Csuzdi E, et al. New non competitive AMPA antagonists. Bioorg Med Chem, 2000, 8(8): 2127-2143.
[2].  Tamási V, Hazai E, Porsmyr-Palmertz M, et al. GYKI-47261, a new AMPA [2-amino-3-(3-hydroxymethylisoxazole-4-yl)propionic acid] antagonist, is a CYP2E1 inducer. Drug Metab Dispos, 2003, 31(11): 1310-1314.
[3].  Bibbiani F, Oh JD, Kielaite A, et al. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol, 2005, 196(2): 422-429.

Featured Products
New Products
 

References on GYKI 47261 dihydrochloride

Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD.[Pubmed:16203001]

Exp Neurol. 2005 Dec;196(2):422-9.

AMPA and NMDA receptors, abundantly expressed on striatal medium spiny neurons, have been implicated in the regulation of corticostriatal synaptic efficacy. To evaluate the contribution of both glutamate receptor types to the pathogenesis of motor response alterations associated with dopaminergic treatment, we studied the ability of the selective AMPA receptor antagonist GYKI-47261 and the selective NMDA receptor antagonists, MK-801 and amantadine, to mitigate these syndromes in rodent and primate models of Parkinson's disease. The effects of GYKI-47261 and amantadine (or MK-801), alone and in combination, were compared for their ability to modify dyskinesias induced by levodopa. In rats, simultaneous administration of subthreshold doses of AMPA and NMDA receptor antagonists completely normalized the wearing-off response to acute levodopa challenge produced by chronic levodopa treatment (P < 0.05). In primates, the glutamate antagonists GYKI-47261 and amantadine, co-administered at low doses (failing to alter dyskinesia scores), reduced levodopa-induced dyskinesias by 51% (P < 0.05). The simultaneous AMPA and NMDA receptor blockade acts to provide a substantially greater reduction in the response alterations induced by levodopa than inhibition of either of these receptors alone. The results suggest that mechanisms mediated by both ionotropic glutamate receptors make an independent contribution to the pathogenesis of these motor response changes and further that a combination of both drug types may provide relief from these disabling complications at lower and thus safer and more tolerable doses than required when either drug is used alone.

New non competitive AMPA antagonists.[Pubmed:11003158]

Bioorg Med Chem. 2000 Aug;8(8):2127-43.

New halogen atom substituted 2,3-benzodiazepine derivatives condensed with an azole ring on the seven membered part of the ring system of type 3 and 4 as well as 5 and 6 were synthesized. It was found that chloro-, dichloro- and bromo-substitutions in the benzene ring and additionally imidazole ring condensation on the diazepine ring can successfully substitute the methylenedioxy group in the well known molecules GYKI 52466 (1) and GYKI 53773 (2) and the 3-acetyl-4-methyl structural feature in 2, respectively, preserving the highly active AMPA antagonist characteristic of the original molecules. From the most active compounds (3b,i) 3b (GYKI 47261) was chosen for detailed investigations. 3b revealed an excellent, broad spectrum anticonvulsant activity against seizures evoked by electroshock and different chemoconvulsive agents indicating a possible antiepileptic efficacy. 3b was found to be highly active in a transient model of focal ischemia predictive of a therapeutic value in human stroke. 3b also reversed the dopamine depleting effect of MPTP and antagonized the oxotremorine induced tremor in mice indicating a potential antiparkinson activity.

Keywords:

GYKI 47261 dihydrochloride,1217049-32-5,Natural Products,AMPAR, buy GYKI 47261 dihydrochloride , GYKI 47261 dihydrochloride supplier , purchase GYKI 47261 dihydrochloride , GYKI 47261 dihydrochloride cost , GYKI 47261 dihydrochloride manufacturer , order GYKI 47261 dihydrochloride , high purity GYKI 47261 dihydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: